Pinc PeptideThe girly peptide research blog

Weight loss · Evidence tier A · #9 in test requests

Semaglutide

Ozempic · Wegovy · Wegovy HD · Rybelsus · Ozempic tablets · Apo-Semaglutide (Canadian generic)

Semaglutide, the drug in Ozempic and Wegovy, cut weight and the risk of heart attack, stroke or heart-related death in large trials12. Unapproved “research” versions often fail tests3.

Last reviewed · First published · 62 sources · 33 min read · By the Pinc Peptide editors

Illustration: a glass vial with a pink label reading Semaglutide
Illustration, not a real product: an empty glass vial (photo: Missouri Historical Society, public domain) with our label. See every vial.

Quick answers

What is it?
A modified version of GLP-1, a gut hormone that helps control blood sugar and appetite613. Novo Nordisk sells it as a weekly injection or daily tablet: Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight loss62223.
Does it work?
Yes, in large trials. People lost 14.9% of their weight on average over 68 weeks, versus 2.4% on placebo1. In overweight people with heart disease, it cut the risk of heart attack, stroke or heart-related death by 20%2. Two Alzheimer’s trials failed19.
Is it safe?
It has known risks. Nausea, diarrhea, vomiting and constipation are common and rise with dose167. It caused thyroid tumors in rats and mice; the risk in people is unknown6. The label also warns of an inflamed pancreas and gallbladder disease6.
Is it legal?
Yes, with a prescription, as Ozempic, Wegovy or Rybelsus46. US pharmacies may no longer make routine copies, because the shortage is over89. Selling “research” vials for human use is illegal in the US2043. Not banned in sport3435.
What is in the vials?
Often not as labeled. As of 30 September 2026, 74 of Finnrick’s latest 196 completed tests failed3. In a 2024 study, all 3 vials bought online held bacterial toxin, one at a raised level3839. Fake “semaglutide” with insulin put two people in a coma10.

What it is

Semaglutide is a modified form of GLP-1 (glucagon-like peptide-1), a gut hormone released after eating. Its 31-amino-acid chain is 94% identical to human GLP-1. Changes protect it from the enzyme DPP-4, and a fatty-acid chain binds it to albumin, the main protein in blood, so one dose lasts about a week613. It switches on the GLP-1 receptor. That raises insulin and lowers glucagon mainly when blood sugar is high, and it slows stomach emptying6. GLP-1 also helps regulate appetite and calorie intake, and in animal studies semaglutide reached and activated neurons in brain areas that control food intake6.

Novo Nordisk, which markets it, designed semaglutide as a once-weekly follow-up to liraglutide, a once-daily GLP-1 drug614. The 2015 discovery paper describes two amino-acid swaps (Aib at position 8, arginine at 34) and a fatty-acid chain on lysine 26, chosen to raise albumin binding and block breakdown14. FDA first approved it as Ozempic on 5 December 20174.

Benefits: what the research shows

Semaglutide is one of the most studied drugs in this catalog. In STEP 1 (1,961 adults with obesity or overweight and no diabetes), 2.4 mg a week plus lifestyle support cut body weight by 14.9% at 68 weeks versus 2.4% with placebo, and half the semaglutide group lost at least 15%1. In STEP UP (1,407 adults), 7.2 mg a week cut weight by 18.7% at 72 weeks versus 15.6% with 2.4 mg and 3.9% with placebo7. A daily 25 mg tablet cut weight by 13.6% versus 2.2% at 64 weeks in OASIS 4 (307 adults)16. In SELECT (17,604 adults with heart disease and overweight but no diabetes), heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide versus 8.0% on placebo over about 40 months, a 20% lower risk2. In FLOW (3,533 adults with type 2 diabetes and kidney disease), 1 mg a week cut the risk of kidney failure, major loss of kidney function, or death from kidney or heart causes by 24%17. In ESSENCE (interim analysis of 800 adults with MASH and liver fibrosis), MASH liver inflammation resolved without worse fibrosis in 62.9% on 2.4 mg versus 34.3% on placebo at 72 weeks18. Not every result is positive. In evoke and evoke+ (3,808 people with early Alzheimer’s disease), daily oral semaglutide did not slow decline on the main dementia rating scale over two years19. Side effects rise with dose. In STEP UP, digestive side effects affected 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysesthesia (unusual or unpleasant skin sensations) affected 22.9%, 6.0% and 0.5%7. In SELECT, 16.6% stopped treatment because of adverse events versus 8.2% on placebo2. All of this evidence comes from the approved, quality-controlled product. It says nothing about the content of unapproved vials sold online, which FDA calls products of unknown quality20.

Key human studies

StudyDesignPeopleDose and routeResult
Wilding et al., N Engl J Med 2021 (STEP 1)1PubMed · DOI · NCT03548935 Randomized, double-blind, placebo-controlled trial (2:1), 68 weeks; adults with BMI 30 or more (27 or more with a weight-related condition), no diabetes 1,961 2.4 mg subcutaneous once weekly plus lifestyle intervention Body weight -14.9% vs -2.4% with placebo (difference -12.4 points). 50.5% vs 4.9% lost 15% or more. Gastrointestinal events led 4.5% vs 0.8% to stop.
Lincoff et al., N Engl J Med 2023 (SELECT)2PubMed · DOI · NCT03574597 Randomized, double-blind, placebo-controlled, event-driven trial; mean follow-up 39.8 months; adults 45 or older with cardiovascular disease, BMI 27 or more, no diabetes 17,604 2.4 mg subcutaneous once weekly Cardiovascular death, heart attack or stroke: 6.5% vs 8.0% (hazard ratio 0.80, 95% CI 0.72 to 0.90). Adverse events led 16.6% vs 8.2% to stop.
Wharton et al., Lancet Diabetes Endocrinol 2025 (STEP UP)7PubMed · DOI · NCT05646706 Phase 3b randomized, double-blind, placebo- and active-controlled trial (5:1:1), 72 weeks; adults with BMI 30 or more, no diabetes 1,407 7.2 mg or 2.4 mg subcutaneous once weekly, or placebo, plus lifestyle intervention Body weight -18.7% (7.2 mg) vs -15.6% (2.4 mg) vs -3.9% (placebo). Dysesthesia 22.9% vs 6.0% vs 0.5%. Serious adverse events 6.8% vs 10.9% vs 5.5%.
Wharton et al., N Engl J Med 2025 (OASIS 4)16PubMed · DOI · NCT05564117 Randomized, double-blind, placebo-controlled trial (2:1), 71 weeks, primary end point at week 64; adults with BMI 30 or more (27 or more with a complication), no diabetes 307 25 mg oral tablet once daily plus lifestyle intervention Body weight -13.6% vs -2.2% with placebo at week 64. Gastrointestinal adverse events 74.0% vs 42.2%.
Sanyal et al., N Engl J Med 2025 (ESSENCE, part 1)18PubMed · DOI · NCT04822181 Phase 3 randomized, double-blind, placebo-controlled trial (2:1), planned 240 weeks; interim analysis of the first 800 patients at week 72; biopsy-proven MASH with fibrosis stage 2 or 3 1,197 2.4 mg subcutaneous once weekly MASH resolution without worse fibrosis 62.9% vs 34.3%. Fibrosis improvement without worse MASH 36.8% vs 22.4%. Body weight -10.5% vs -2.0%.
Cummings et al., Lancet 2026 (evoke and evoke+)19PubMed · DOI · NCT04777396 Two phase 3 randomized, double-blind, placebo-controlled trials (evoke, NCT04777396; evoke+, NCT04777409), up to 156 weeks; amyloid-confirmed early Alzheimer’s disease, ages 55 to 85 3,808 Oral semaglutide up to 14 mg once daily (flexible dose) No benefit. Change in CDR-SB dementia score at week 104 differed from placebo by -0.08 (p=0.57) in evoke and 0.10 (p=0.46) in evoke+. Both trials were stopped for a negative outcome.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

Approved labels: Wegovy injection starts at 0.25 mg once weekly and rises every 4 weeks (0.5, 1, 1.7 mg) to a maintenance dose of 2.4 mg (recommended) or 1.7 mg. Adults who tolerate 2.4 mg for at least 4 weeks may go up to 7.2 mg weekly if more weight loss is needed. Wegovy tablets start at 1.5 mg daily and rise every 30 days (4 mg, 9 mg) to 25 mg daily6. Ozempic starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, up to a maximum of 2 mg weekly22. Rybelsus starts at 3 mg daily for 30 days, then 7 mg, then 14 mg if needed23. Trial doses: 2.4 mg weekly in STEP 1, SELECT and ESSENCE; 7.2 mg weekly in STEP UP; 1 mg weekly in FLOW; 25 mg daily by mouth in OASIS 4; up to 14 mg daily by mouth in evoke and evoke+12716171819.

In animal studies

Two-year cancer studies on the US label: mice received 0.3, 1 or 3 mg/kg/day (males) and 0.1, 0.3 or 1 mg/kg/day (females) under the skin; rats received 0.0025, 0.01, 0.025 or 0.1 mg/kg/day. Thyroid C-cell adenomas increased at every dose in both species, and C-cell carcinomas increased in male rats at 0.01 mg/kg/day and above6. In mini-pigs, plasma half-life after an intravenous dose was 46.1 hours14. These are animal doses, not human doses.

What users report Anecdotal · not validated · not a recommendation

“Microdosing” is described as 25% to 50% of the manufacturer’s recommended starting dose, or doses spaced further apart than the labeled schedule. A 2026 commentary says the practice gained traction during recent shortages through patient communities, telemedicine weight-loss programs and clinician anecdotes, and that high-quality evidence is essentially absent37.

Half-life
About 1 week6Elimination half-life in adults with overweight or obesity (Wegovy label). Semaglutide stays in the blood for about 5 to 7 weeks after the last dose. Bioavailability is 89% by injection under the skin and about 1% to 2% by tablet.
Routes
  • Subcutaneous injection once weekly (approved as Ozempic and Wegovy; human trial data)
  • Oral tablet once daily (approved as Rybelsus, Ozempic tablets and Wegovy tablets; human trial data)
  • Unapproved “research” vials sold for injection (no quality control; no trials of these products found)

Every dose studied for Semaglutide, with sources →

Quality and the gray market

What testing finds

Independent tests show frequent problems with unapproved semaglutide. As of 30 September 2026, Finnrick had published 373 tests of semaglutide from 71 vendors. Of the latest 200, 122 passed, 74 failed and 4 were incomplete, a 37.8% fail rate among completed tests3. In a 2024 study, researchers ordered from 6 illegal online pharmacies. Only the 3 vial orders arrived. They held 28.6% to 38.7% more semaglutide than labeled, purity was 7.7% to 14.4% versus 99% claimed, and endotoxin, a bacterial toxin, was found in all three, at a raised level in one3839. The 3 Ozempic pen orders were never delivered, and the sellers demanded fake “customs” fees of $650 to $1,20039. On 14 September 2026 ABC News reported a TGA safety advisory: a product sold as retatrutide contained no retatrutide but held semaglutide at about eight times the level found in semaglutide products the TGA had assessed40. FDA warns that counterfeit Ozempic in the US may contain the wrong ingredients, or too little, too much or none of the active ingredient20.

How it is sold

Unapproved semaglutide is sold online as freeze-dried powder in vials38, often labeled “for research purposes” or “not for human consumption”. FDA says it has warned companies that sold such products directly to consumers with dosing instructions20. Code names do not change the legal status: FDA warning letters listed “GLP1-S” (31 March 2026) and “GLP-1 S (Semaglutide)” (24 August 2026) as unapproved new drugs4142. In letters dated 23 September 2026 and 24 September 2026, FDA said two websites selling “Semanat Injection (Semaglutide)” and “Semanext Injection” introduce “unapproved and misbranded injectable semaglutide drug products” into interstate commerce6162. DOJ has prosecuted sellers. On 23 July 2026 it announced a 21-month prison sentence for a Michigan man in a misbranding conspiracy case; the websites he sold through offered semaglutide and tirzepatide from China as “for research purposes only”43. On 15 April 2025 it announced that a Kentucky doctor had pleaded guilty to distributing misbranded semaglutide, some of it from vials labeled for lab research44. EMA and national EU regulators warned on 3 September 2025 of a sharp rise in illegal medicines sold as GLP-1 drugs45. Tester data suggest gray-market demand for semaglutide is modest next to newer drugs: by our count from Finnrick’s chart data, it drew 2.0% (434) of 21,253 test requests from May 2025 to May 2026, versus 34.6% for retatrutide46. On 30 September 2026, r/Semaglutide had 73,222 weekly visitors and r/Ozempic had 51,3114748. On a US Google Trends scale where the peak week for “peptides” is 100, “semaglutide” stayed at about 20 to 31 from January 2024 to September 202649. Legal cash prices have fallen. Wegovy cost $499 a month through NovoCare Pharmacy from 5 March 202550. The Wegovy pill launched on 5 January 2026 at $149 a month for the starting dose51. On 6 February 2026 the White House said TrumpRx prices for Ozempic and Wegovy injections average $350 a month and go as low as $19952. On 8 October 2026 NovoCare Pharmacy listed Wegovy injection at $349 a month for doses up to 2.4 mg and $399 for 7.2 mg, with $199 a month for new patients’ first two fills at 0.25 mg or 0.5 mg60. Finnrick showed gray-market prices of $1.00 to $28.33 per mg for its eight top-scored semaglutide sellers (tests through 20 September 2026)3. In a KFF poll published 14 November 2025, 17% of US adults who had taken a GLP-1 got it from an online provider or website and 9% from a medical spa53.

Side effects and risks

  • Digestive side effects are the most common (nausea, diarrhea, vomiting, constipation) and rise with dose67. In STEP 1, 4.5% stopped because of them versus 0.8% on placebo1.
  • Boxed warning: semaglutide causes thyroid C-cell tumors in rodents, and whether it does in humans is unknown. It is not for people with a personal or family history of medullary thyroid cancer or MEN 26.
  • Other label warnings: acute pancreatitis, gallbladder disease, low blood sugar when combined with insulin or drugs that boost insulin release, kidney injury from dehydration, severe digestive reactions, serious allergic reactions, diabetic eye complications, a faster heart rate, and inhaling stomach contents during anesthesia or deep sedation6. The label also says the four-dose Wegovy FlexTouch pen must never be shared between patients, even if the needle is changed, because of the risk of passing on blood-borne infections6.
  • Higher doses bring more side effects. At 7.2 mg, 22.9% reported dysesthesia versus 6.0% at 2.4 mg7.
  • Vision: EMA lists NAION, an optic-nerve injury that can cause vision loss, as a very rare side effect (up to 1 in 10,000 people). The 2026 US Wegovy, Ozempic and Rybelsus labels reviewed here do not list it6222326.
  • Mood: the Wegovy label dropped its warning on suicidal behavior and ideation in February 20266.
  • Dosing errors: FDA has received reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded injectable semaglutide, by patients measuring their own doses or by clinicians miscalculating them20.
  • Gray-market products can hold the wrong amount, bacterial endotoxin or a different drug, including insulin103840.
  • Legal risk: selling unapproved “research” semaglutide for human use is illegal in the US, and sellers have gone to prison2043.

Documented harms

  • 14 Sep 2026Australia: ABC News reported a TGA safety advisory about a user of a product sold as retatrutide who had uncontrollable vomiting, suffered a torn esophagus and needed hospital care. Testing found no retatrutide, but semaglutide at about eight times the level in semaglutide products the TGA had assessed.40
  • 29 Jun 2026Two people without diabetes or obesity, described in a Dutch medical journal, fell into a coma with severe low blood sugar after injecting “semaglutide” obtained without a prescription. It contained synthetic insulin, and they needed up to two days of glucose infusion.10
  • 17 Jun 2026A UT San Antonio study of US poison-center data reported that calls about GLP-1 receptor agonists rose from about 1,000 to 1,500 a year before 2021 to more than 8,000 in 2023, mostly from unintentional dosing or therapeutic errors.54
  • 31 May 2026FDA had received 990 adverse-event reports tied to compounded semaglutide. FDA says these events are likely underreported because state-licensed pharmacies that are not outsourcing facilities do not have to report them.20
  • 30 Jan 2026Case report: an 18-year-old woman developed euglycemic ketoacidosis (a dangerous acid build-up with normal blood sugar) 10 days after starting semaglutide bought online and raising the dose herself without supervision. She was discharged after 36 hours.55
  • 29 Jan 2026UK: the MHRA reported 1,296 Yellow Card reports of pancreatitis with GLP-1 and dual GIP/GLP-1 medicines from 2007 to October 2025 and strengthened its warnings.28

Questions people ask

Is semaglutide FDA approved?

Yes. It is approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy injection and tablets for weight management and heart risk reduction46. Semaglutide sold online as a “research” product is not an approved drug20.

Is “research” semaglutide safe?

FDA says these products are of unknown quality and may be harmful20. In Finnrick’s latest 200 tests, 37.8% of completed samples failed (as of 30 September 2026), and fake “semaglutide” that contained insulin put two people in a coma310.

Wegovy vs Ozempic: what’s the difference?

Both are once-weekly semaglutide injections from Novo Nordisk. Ozempic is labeled for type 2 diabetes at up to 2 mg a week. Wegovy is labeled for weight management, heart risk reduction and MASH at 2.4 mg a week, with up to 7.2 mg for weight loss in adults622.

Is semaglutide banned in sports?

No. WADA does not prohibit it in 2026 or 2027, but it is on WADA’s Monitoring Program and WADA has started a second study of its effects on athletes1236.

How long does semaglutide stay in your body?

Its half-life is about one week, so it stays in the blood for about 5 to 7 weeks after the last dose6.

What is still unknown

  • How much gray-market “semaglutide” is a salt form (sodium or acetate), which FDA says has no lawful basis for compounding, is unknown.
  • We found no controlled trial of “microdosing” regimens, so their effects on weight and safety are unknown.
  • EMA lists NAION as a very rare side effect, but the US labels reviewed (June to August 2026 versions) do not mention it. FDA’s current position was not checked.
  • Not verified, so left out: a January 2026 EU opinion for a product called Kayshild, Indian generic launches in March 2026, a June 2026 Canadian generic weight-loss launch, and whether Wegovy HD was the first GLP-1 approved under FDA’s national priority voucher pilot.
  • When Apotex’s tentatively approved US generic could be sold depends on patents and exclusivity, which were not reviewed.
  • Finnrick does not explain how its price-per-mg figures are derived, and its counts change as new tests are posted.
  • CDC data on emergency visits for semaglutide side effects (Ann Intern Med 2025) were not read.
  • UK marketing status, and rules outside the US, EU, UK, Canada and Australia, were not verified.

Sources

  1. 1Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine, 2021. pubmed.ncbi.nlm.nih.gov
  2. 2Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine, 2023. pubmed.ncbi.nlm.nih.gov
  3. 3Semaglutide: public lab test results (Finnrick product page) Finnrick, 29 Sep 2026. finnrick.com
  4. 4Drugs@FDA: applications containing semaglutide (NDA 209637, 213051, 213182, 215256, 218316; ANDA 220314) U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
  5. 5FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults Novo Nordisk (PR Newswire), 22 Dec 2025. prnewswire.com
  6. 6WEGOVY (semaglutide) injection and tablets: prescribing information (SPL version 19) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 30 Jun 2026. dailymed.nlm.nih.gov
  7. 7Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology, Nov 2025. pubmed.ncbi.nlm.nih.gov
  8. 8FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize U.S. Food and Drug Administration, 1 Apr 2026. fda.gov
  9. 9Outsourcing Facilities Ass’n v. FDA, No. 25-10758 (5th Cir.) (unpublished, per curiam; revised) US Court of Appeals for the Fifth Circuit, 1 Sep 2026. ca5.uscourts.gov
  10. 10[Insulin intoxications caused by falsified semaglutide] Nederlands Tijdschrift voor Geneeskunde, 29 Jun 2026. pubmed.ncbi.nlm.nih.gov
  11. 11The 2026 Monitoring Program World Anti-Doping Agency, Sep 2025. wada-ama.org
  12. 12The 2027 Monitoring Program World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  13. 13KEGG DRUG: Semaglutide (D10025) KEGG, Kanehisa Laboratories, accessed 8 Oct 2026. kegg.jp
  14. 14Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of Medicinal Chemistry, 2015. pubmed.ncbi.nlm.nih.gov
  15. 15PubChem compound CID 56843331: Semaglutide (formula and weight) NCBI PubChem, accessed 1 Oct 2026. pubchem.ncbi.nlm.nih.gov
  16. 16Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine, 2025. pubmed.ncbi.nlm.nih.gov
  17. 17Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes New England Journal of Medicine, 2024. pubmed.ncbi.nlm.nih.gov
  18. 18Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis New England Journal of Medicine, 2025. pubmed.ncbi.nlm.nih.gov
  19. 19Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials The Lancet, 2026. pubmed.ncbi.nlm.nih.gov
  20. 20FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 1 Oct 2026. fda.gov
  21. 21FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight U.S. Food and Drug Administration, 8 Mar 2024. fda.gov
  22. 22OZEMPIC (semaglutide) injection: prescribing information (SPL version 20) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 10 Jun 2026. dailymed.nlm.nih.gov
  23. 23RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information (SPL version 14) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 19 Aug 2026. dailymed.nlm.nih.gov
  24. 24Drugs@FDA Glossary of Terms U.S. Food and Drug Administration, 14 Nov 2017. fda.gov
  25. 25Warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (MARCS-CMS 738238) U.S. Food and Drug Administration, 18 Sep 2026. fda.gov
  26. 26PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy European Medicines Agency, 6 Jun 2025. ema.europa.eu
  27. 27First oral GLP-1 treatment for weight management European Medicines Agency, 22 May 2026. ema.europa.eu
  28. 28MHRA updates guidance for GLP-1 prescribers and patients Medicines and Healthcare products Regulatory Agency (GOV.UK), 29 Jan 2026. gov.uk
  29. 29Prescription Drug List: Human Use Health Canada (Drug and Health Product Register), accessed 30 Sep 2026. hpr-rps.hres.ca
  30. 30Generic Ozempic is now on Canadian shelves. Is it the same as the brand name version? CBC News, 20 May 2026. cbc.ca
  31. 31Apo-Semaglutide Injection: Incorrect dose display Health Canada, 27 Aug 2026. recalls-rappels.canada.ca
  32. 32Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  33. 33Therapeutic Goods Legislation Amendment (2024 Measures No. 2) Regulations 2024 (F2024L00686) Federal Register of Legislation, Australian Government, 14 Jun 2024. legislation.gov.au
  34. 34World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  35. 35World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  36. 36WADA publishes 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  37. 37Considerations and challenges in microdosing of GLP-1-based receptor agonists Expert Opinion on Pharmacotherapy, 5 Oct 2026. pubmed.ncbi.nlm.nih.gov
  38. 38Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study Journal of Medical Internet Research, 2024. pubmed.ncbi.nlm.nih.gov
  39. 39Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases JAMA Network Open, 1 Aug 2024. pubmed.ncbi.nlm.nih.gov
  40. 40Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings ABC News (Australia), 14 Sep 2026. abc.net.au
  41. 41Warning letter to Prime Sciences (MARCS-CMS 721805) U.S. Food and Drug Administration, 31 Mar 2026. fda.gov
  42. 42Warning letter to Peptide Partners LLC (MARCS-CMS 735063) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  43. 43Gobles Man Sentenced for Selling Chinese Drugs Without FDA Approval U.S. Attorney’s Office, Western District of Michigan, 23 Jul 2026. justice.gov
  44. 44Ashland Doctor Pleads Guilty to Distribution of Misbranded Semaglutide U.S. Attorney’s Office, Eastern District of Kentucky, 15 Apr 2025. justice.gov
  45. 45Warning about sharp rise in illegal medicines sold in the EU European Medicines Agency, 3 Sep 2025. ema.europa.eu
  46. 46We’d Rather Buy the Future Than Wait For It Finnrick, 10 Jun 2026. finnrick.com
  47. 47r/Semaglutide (official subreddit embed page; weekly visitors) Reddit, accessed 30 Sep 2026. embed.reddit.com
  48. 48r/Ozempic (official subreddit embed page; weekly visitors) Reddit, accessed 30 Sep 2026. embed.reddit.com
  49. 49Google Trends: interest over time, United States, January 2024 to September 2026 (peptides, semaglutide) Google Trends, accessed 30 Sep 2026. trends.google.com
  50. 50Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients Novo Nordisk (PR Newswire), 5 Mar 2025. prnewswire.com
  51. 51Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Novo Nordisk (PR Newswire), 5 Jan 2026. prnewswire.com
  52. 52President Trump Launches TrumpRx.gov, Delivering Massive, Immediate Savings to Millions of Americans The White House, 6 Feb 2026. whitehouse.gov
  53. 53Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford KFF, 14 Nov 2025. kff.org
  54. 54UT San Antonio study: As FDA approved semaglutide for weight management, calls to poison control centers skyrocketed in the U.S. UT San Antonio, 17 Jun 2026. news.utsa.edu
  55. 55Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss Cureus, 30 Jan 2026. pubmed.ncbi.nlm.nih.gov
  56. 56Apo-Semaglutide Injection: Incorrect dose display (RA-82679) Health Canada, 25 Sep 2026. recalls-rappels.canada.ca
  57. 57Wegovy: EPAR - Procedural steps taken and scientific information after authorisation European Medicines Agency, 21 Sep 2026. ema.europa.eu
  58. 58Semaglutide Injection: Incorrect Pen in Package (RA-82477) Health Canada, 12 Aug 2026. recalls-rappels.canada.ca
  59. 59Semaglutide Injection: Out-of-Specification (Impurity) (RA-82537) Health Canada, 27 Aug 2026. recalls-rappels.canada.ca
  60. 60Get Your GLP-1 Medications Delivered with NovoCare Pharmacy Novo Nordisk (NovoCare), accessed 8 Oct 2026. novocare.com
  61. 61Warning letter to Online Generic Medicine, www.onlinegenericmedicine.com (MARCS-CMS 737806) U.S. Food and Drug Administration, 23 Sep 2026. fda.gov
  62. 62Warning letter to Cheap Medicine Shop, www.cheapmedicineshop.com (MARCS-CMS 737810) U.S. Food and Drug Administration, 24 Sep 2026. fda.gov

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.